Viking Therapeutics Presents Results from Study of VK0214 in In Vivo Model of X-ALD

SAN DIEGO, Oct. 23, 2017 (PRNewswire) — Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive results from a 25-week proof-of-concept study of VK0214 in an in vivo model of X-linked adrenoleukodystrophy (X-ALD).  The final study data were presented in a poster presentation at the 87th Annual Meeting of the American Thyroid Association (ATA), held October 18-22, 2017, in Victoria, British Columbia.

The results of this study showed that treatment with VK0214 led to statistically significant reductions in plasma levels of multiple very long chain fatty acids (VLCFAs), including the benchmark highly toxic C26 fatty acid, in treated animals compared with vehicle controls.  VLCFA levels in CNS tissues were also significantly reduced, suggesting a potential direct benefit in both brain and spinal cord.  As the accumulation of VLCFAs is believed to contribute to the underlying pathology of X-ALD, these data provide additional support for the role of selective thyroid receptor beta (TRb) activation as a potential therapeutic approach to the disease.

To read the full story, click here.


Source: PR Newswire